

# Synthesis of Fully Substituted Pyrazoles via Regio- and Chemoselective Metalations


Christina Despotopoulou, Lydia Klier, and Paul Knochel\*

Department Chemie & Biochemie, Ludwig-Maximilians-Universität, Butenandtstrasse 5-13, 81377 München, Germany

paul.knochel@cup.uni-muenchen.de

Received May 29, 2009

## ABSTRACT



The full functionalization of the pyrazole ring was achieved by successive regioselective metalations using  $\text{TMPMgCl}\cdot\text{LiCl}$  and  $\text{TMP}_2\text{Mg}\cdot 2\text{LiCl}$ . Trapping with various electrophiles led to trisubstituted pyrazoles. An application to the synthesis of the acaricide Tebufenpyrad is reported.

Pyrazole derivatives display a broad spectrum of biological activities and are used as cholesterol-lowering,<sup>1</sup> anti-inflammatory,<sup>2</sup> anticancer,<sup>3</sup> antidepressant, and antipsychotic<sup>4</sup> agents. They are therefore attractive building blocks for pharmaceutical research, and pyrazoles are present in leading pharmaceuticals (e.g., Celebrex,<sup>2</sup> Viagra<sup>5</sup>). These heterocycles have also found applications in the agrochemical industry and recently in the field of photoprotectors, ultraviolet stabilizers, and energetic materials.<sup>6</sup>

As a result, there is a constant striving to develop new methods for the synthesis of highly substituted pyrazoles. So far, the main access to fully functionalized pyrazoles

involves condensation reactions between hydrazines and 1,3-dicarbonyl compounds and their derivatives<sup>7</sup> or 1,3-dipolar cycloadditions.<sup>8</sup> However, some limitations of these methods are the poor regioselectivity, multistep synthesis of the starting materials, and the harsh conditions often used.<sup>9</sup>

(1) Sliskovic, D. R.; Roth, B. D.; Wilson, M. W.; Hoefle, M. L.; Newton, R. S. *J. Med. Chem.* **1990**, *33*, 31.

(2) Penning, T. D.; Talley, J. J.; Bertenshaw, S. R.; Carter, J. S.; Collins, P. W.; Docter, S.; Graneto, M. J.; Lee, L. F.; Malecha, J. W.; Miyashiro, J. M.; Rogers, R. S.; Rogier, D. J.; Yu, S. S.; Anderson, G. D.; Burton, E. G.; Cogburn, J. N.; Gregory, S. A.; Koboldt, C. M.; Perkins, W. E.; Seibert, K.; Veenhuizen, A. W.; Zhang, Y. Y.; Isakson, P. C. *J. Med. Chem.* **1997**, *40*, 1347.

(3) Stauffer, S. R.; Katzenellenbogen, J. A. *J. Comb. Chem.* **2000**, *2*, 318.

(4) Moore, K. W.; Bonner, K.; Jones, E. A.; Emms, F.; Leeson, P. D.; Marwood, R.; Patel, S.; Rowley, M.; Thomas, S.; Carling, R. W. *Bioorg. Med. Chem. Lett.* **1999**, *9*, 1285.

(5) Terrett, N. K.; Bell, A. S.; Brown, D.; Ellis, P. *Bioorg. Med. Chem. Lett.* **1996**, *6*, 1819.

(6) (a) Elguero, J. In *Comprehensive Heterocyclic Chemistry*; Katritzky, A. R., Ed.; Pergamon Press: New York, 1984; Vol. 5, pp 291–297. (b) Elguero, J. In *Comprehensive Heterocyclic Chemistry II*; Shinkai, I., Ed.; Elsevier: Oxford, 1996; Vol. 3, pp 3–75. (c) Elguero, J.; Goya, P.; Jagerovic, N.; Silva, A. M. S. *Targets Heterocycl. Syst.* **2002**, *6*, 52. (d) *Progress in Heterocyclic Chemistry*; Gribble, G. W., Joule, J., Eds.; Elsevier: Oxford, 2007; Vol. 18. (e) Cavero, E.; Uriel, S.; Romero, P.; Serrano, J. L.; Gimenez, R. *J. Am. Chem. Soc.* **2007**, *129*, 11608. (f) Catalán, J.; Fabero, F.; Guijano, M. S.; Claramunt, R. M.; Maria, M. D. S.; Foces-Foces, M. C.; Cano, F. H.; Elguero, J.; Sastre, R. *J. Am. Chem. Soc.* **1990**, *112*, 747. (g) Catalán, J.; Fabero, F.; Claramunt, R. M.; Maria, M. D. S.; Foces-Foces, M. C.; Cano, F. H.; Martínez-Ripoll, M.; Elguero, J.; Sastre, R. *J. Am. Chem. Soc.* **1992**, *114*, 5039. (h) Ye, C.; Gard, G. L.; Winter, R. W.; Syvret, R. G.; Twamley, B.; Shreeve, J. M. *Org. Lett.* **2007**, *9*, 3841.


(7) (a) Kost, A. N.; Grandberg, I. I. *Adv. Heterocycl. Chem.* **1996**, *6*, 347. (b) Heller, S. T.; Natarajan, S. R. *Org. Lett.* **2006**, *8*, 2675. (c) Zefirov, N. S.; Kozhushkov, S. I.; Kuznetsova, T. S. *Tetrahedron* **1982**, *38*, 1693. (d) Kokoreva, O. V.; Averina, E. B.; Ivanova, O. A.; Kozhushkov, S. I.; Kuznetsova, T. S. *Chem. Heterocycl. Compd.* **2001**, *37*, 834. (e) Ahmed, M. S.; Kobayashi, K.; Mori, A. *Org. Lett.* **2005**, *7*, 4487. (f) Alex, K.; Tillack, A.; Schwarz, N.; Beller, M. *Org. Lett.* **2008**, *10*, 2377.

(8) (a) Padwa, A. *1,3-Dipolar Cycloaddition Chemistry*; John Wiley & Sons: New York, 1984; Vol. 1. (b) Martin, R.; Rodriguez Rivero, M.; Buchwald, S. L. *Angew. Chem., Int. Ed.* **2006**, *45*, 7079. (c) Aggarwal, V. K.; de Vicente, J.; Bonnert, R. V. *J. Org. Chem.* **2003**, *68*, 5381.

Deprotonation reactions on the pyrazole ring were until now limited to lithiations at very low temperatures on the most acidic C5 position.<sup>10</sup> Functionalization at the C3 position of the pyrazole core was only possible through a protecting group switch, while the C4 position was accessed through electrophilic substitutions.<sup>11</sup> Recently, we reported the new mixed Li/Mg bases TMPMgCl·LiCl (**1**; TMP = 2,2,6,6-tetramethyl-piperidyl)<sup>12</sup> and the more reactive TMP<sub>2</sub>Mg·2LiCl (**2**),<sup>13</sup> which allow the magnesiation of functionalized arenes and heteroarenes. Sensitive substrates can be efficiently metalated using the milder base TMP<sub>2</sub>Zn·2MgCl<sub>2</sub>·2LiCl (**3**).<sup>14</sup>

Herein, we report a new regio- and chemoselective synthesis of fully substituted pyrazoles through successive metalations on easily accessible pyrazoles (Scheme 1).

**Scheme 1.** Full Functionalization of Pyrazoles through Successive Metallations using TMPMgCl·LiCl (**1**) and TMP<sub>2</sub>Mg·2LiCl (**2**)



Starting from the SEM-protected pyrazole<sup>15</sup> **4a** or the commercially available 1-methyl-1*H*-pyrazole (**4b**), magnesiation of the C5 position could be achieved using TMPMgCl·LiCl<sup>12</sup> (**1**; 1.1 equiv, 25 °C, THF, 1 h). The resulting magnesiated pyrazole **5a** successfully undergoes, after transmetalation with ZnCl<sub>2</sub>, a Negishi<sup>16</sup> cross-coupling furnishing the expected product **6a** in 91% yield. Trapping of **5a** with various electrophiles such as Et<sub>3</sub>SiCl, PhSO<sub>2</sub>SPh, and MeSO<sub>2</sub>SMe<sup>17</sup> gave the corresponding 5-substituted pyrazoles **6b–d** in 72–84% yield. Similarly, the 5-magne-


(9) (a) Heller, S. T.; Natarajan, S. R. *Org. Lett.* **2006**, *8*, 2675. (b) Deng, X.; Mani, N. S. *Org. Lett.* **2008**, *10*, 1307.

(10) (a) *Science of Synthesis*; Stanovnik, B., Svete, J. D., Eds.; Thieme: Stuttgart, 2002; Vol. 12, pp 173–203. (b) Gupta, R. R.; Kumar, M.; Gupta, V. *Heterocyclic Chemistry*; Springer: Berlin, 1998; p 452. (c) Behr, L. C.; Fusco, R.; Jarboe, C. H. Pyrazoles, pyrazolines, pyrazolidines, indazoles and condensed rings. In *The Chemistry of Heterocyclic Compounds*; Wiley, R. H., Ed.; Interscience Publishers: New York, 1967; Vol. 22, pp 107–109. (d) L'Helgoual'ch, J.-M.; Seggio, A.; Chevallier, F.; Yonehara, M.; Jeanneau, E.; Uchiyama, M.; Mongin, F. *J. Org. Chem.* **2008**, *73*, 177. (e) Schlosser, M.; Volle, J.-N.; Leroux, F.; Schenk, K. *Eur. J. Org. Chem.* **2002**, 2913. (f) Gérard, A.-L.; Bouillon, A.; Mahatsekake, C.; Collot, V.; Rault, S. *Tetrahedron Lett.* **2006**, *47*, 4665. (g) Balle, T.; Vedso, P.; Begtrup, M. *J. Org. Chem.* **1999**, *64*, 5366. (h) Alley, P. W.; Shirley, D. A. *J. Am. Chem. Soc.* **1958**, *80*, 6271. (i) Subramanyam, C. *Synth. Commun.* **1995**, *25*, 761.

(11) (a) McLaughlin, M.; Marcantonio, K.; Chen, C.-Y.; Davies, I. W. *J. Org. Chem.* **2008**, *73*, 4309. (b) Goikhman, R.; Jacques, T. L.; Sames, D. *J. Am. Chem. Soc.* **2009**, *131*, 3042.

siated *N*-methylpyrazole **5b** provides after reaction with MeSO<sub>2</sub>SMe, PhSO<sub>2</sub>SPh, and Et<sub>3</sub>SiCl the new substituted pyrazole derivatives **7a–c** in 79–83% yields (Scheme 2).

**Scheme 2.** Magnesiation of Pyrazole Derivatives of Type **4** at Position 5 using TMPMgCl·LiCl (**1**)



A subsequent deprotonation at position 3 is readily achieved by adding TMPMgCl·LiCl (**1**) to various 5-substituted pyrazoles of type **6** and **7**. Thus, treatment of the SEM-protected pyrazoles **6c** and **6d** with TMPMgCl·LiCl (**1**; 1.1 equiv, –15 °C, 10 h) and subsequent quenching with TsCN, NCCO<sub>2</sub>Et, FCl<sub>2</sub>CCCIF<sub>2</sub>,<sup>18</sup> (BrCl<sub>2</sub>)<sub>2</sub>, and DMF furnished the 3,5-disubstituted pyrazoles **8a–e** in 65–76% yield (entries 1–5 of Table 1).

Similarly, the *N*-methylated pyrazoles **7a** and **7b** were magnesiated under the same conditions. Metalation of **7a** using TMPMgCl·LiCl (**1**) followed by the transmetalation with CuCN·2LiCl<sup>19</sup> and addition of benzoyl chloride gave the expected ketone **9a** in 78% yield (entry 6). Magnesiation of the pyrazole **7b** gave after chlorination with FCl<sub>2</sub>CCCIF<sub>2</sub><sup>18</sup> (–15 to 25 °C, 5 h) the chloro derivative **9b** in 69% yield (entry 7). In the presence of CuCN·2LiCl<sup>19</sup> an allylation with allyl bromide furnished the pyrazole **9c** in 78% yield, after magnesiation with TMPMgCl·LiCl (**1**) (entry 8). The 5-si-

(12) (a) Krasovskiy, A.; Krasovskaya, V.; Knochel, P. *Angew. Chem., Int. Ed.* **2006**, *45*, 2958. (b) Lin, W.; Baron, O.; Knochel, P. *Org. Lett.* **2006**, *8*, 5673. (c) Garcia-Alvarez, P.; Graham, D. V.; Hevia, E.; Kennedy, A. R.; Klett, J.; Mulvey, R. E.; O'Hara, C. T.; Weatherstone, S. *Angew. Chem., Int. Ed.* **2008**, *47*, 8079. (d) Mulvey, R. E. *Organometallics* **2006**, *25*, 1060. (e) Mulvey, R. E. *Chem. Commun.* **2001**, 1049. (f) Westerhausen, M. *Dalton Trans.* **2006**, 4755. (g) Mulvey, R. E.; Mongin, F.; Uchiyama, M.; Kondo, Y. *Angew. Chem., Int. Ed.* **2007**, *46*, 3802. (h) Mosrin, M.; Knochel, P. *Org. Lett.* **2008**, *10*, 2497. (i) Mosrin, M.; Boudet, N.; Knochel, P. *Org. Biomol. Chem.* **2008**, *6*, 3237.

(13) (a) Clososki, G. C.; Rohbogner, C. J.; Knochel, P. *Angew. Chem., Int. Ed.* **2007**, *46*, 7681. (b) Rohbogner, C. J.; Clososki, G. C.; Knochel, P. *Angew. Chem., Int. Ed.* **2008**, *47*, 1503.

(14) (a) Wunderlich, S. H.; Knochel, P. *Angew. Chem., Int. Ed.* **2007**, *46*, 7685. (b) Mosrin, M.; Knochel, P. *Chem.—Eur. J.* **2009**, *15*, 1468. (c) Hlavinka, M. L.; Hagadorn, J. R. *Tetrahedron Lett.* **2006**, *47*, 5049. (d) Seggio, A.; Chevallier, F.; Vaultier, M.; Mongin, F. *J. Org. Chem.* **2007**, *72*, 6602. (e) Mosrin, M.; Knochel, P. *Org. Lett.* **2009**, *11*, 1837.

(15) Fugina, N.; Holzer, W.; Wasicky, M. *Heterocycles* **1992**, *34*, 303.

(16) (a) Negishi, E.; Valente, L. F.; Kobayashi, M. *J. Am. Chem. Soc.* **1980**, *102*, 3298. (b) Negishi, E.; Kobayashi, M. *J. Org. Chem.* **1980**, *45*, 5223. (c) Negishi, E. *Acc. Chem. Res.* **1982**, *15*, 340. (d) Milne, J. E.; Buchwald, S. L. *J. Am. Chem. Soc.* **2004**, *126*, 13028.

(17) The thiomethyl or thiophenyl group can be subjected to cross-coupling reactions; see: Liebeskind, L. S.; Srogl, J. *Org. Lett.* **2002**, *4*, 979.

(18) Marzi, E.; Bobbio, C.; Cottet, F.; Schlosser, M. *Eur. J. Org. Chem.* **2005**, *10*, 2116.

(19) Knochel, P.; Yeh, M. C. P.; Berk, S. C.; Talbert, J. *J. Org. Chem.* **1988**, *53*, 2390.

**Table 1.** Disubstituted Pyrazoles of Type **8** and **9** Obtained by Regioselective Magnesiation of Pyrazoles of Type **6** and **7** with  $\text{TMPMgCl}\cdot\text{LiCl}$  (**1**) and Quenching with Electrophiles

entry	substrate	electrophile	product	yield (%) <sup>a</sup>
1		TsCN		68 <sup>b</sup>
2	<b>6c</b>	NCCO <sub>2</sub> Et		71 <sup>b</sup>
3	<b>6c</b>	FCI <sub>2</sub> CCCFI <sub>2</sub>		65 <sup>b</sup>
4		(BrCl <sub>2</sub> C) <sub>2</sub>		75 <sup>b</sup>
5	<b>6d</b>	DMF		76 <sup>b</sup>
6		PhCOCl		78 <sup>b,c</sup>
7		FCI <sub>2</sub> CCCFI <sub>2</sub>		69 <sup>b</sup>
8	<b>7b</b>	Br-CH <sub>2</sub> -CH=CH <sub>2</sub>		78 <sup>b,d</sup>
9		TsCN		61 <sup>c</sup>

<sup>a</sup> Isolated, analytically pure product. <sup>b</sup> Deprotonation conditions:  $\text{TMPMgCl}\cdot\text{LiCl}$  (**1**; 1.1 equiv),  $-15^\circ\text{C}$ , 10 h. <sup>c</sup> Transmetalation with 1.1 equiv of  $\text{CuCN}\cdot 2\text{LiCl}$ . <sup>d</sup> Catalyzed with 5 mol % of  $\text{CuCN}\cdot 2\text{LiCl}$ . <sup>e</sup> Deprotonation conditions:  $\text{TMPMgCl}\cdot\text{LiCl}$  (**1**; 1.1 equiv),  $25^\circ\text{C}$ , 2 h.

ylated pyrazole **7c** was deprotonated using  $\text{TMPMgCl}\cdot\text{LiCl}$  (**1**; 1.1 equiv,  $25^\circ\text{C}$ , 2 h). Subsequent reaction with TsCN afforded the corresponding nitrile **9d** in 61% yield (entry 9).

The remaining position 4 of the pyrazole core was smoothly magnesiated using the stronger base  $\text{TMP}_2\text{Mg}\cdot 2\text{LiCl}$ <sup>13</sup> (**2**; 1.1 equiv,  $-20^\circ\text{C}$ , 4 h). Thus, the disubstituted pyrazole **8c** was deprotonated at position 4 and treated with benzaldehyde or DMF giving the corresponding alcohol **10a** in 71% yield or aldehyde **10b** in 67% yield (entries 1 and 2 of Table 2). The deprotonation of **8d** under the same conditions gave after transmetalation with  $\text{CuCN}\cdot 2\text{LiCl}$ <sup>19</sup> the


**Table 2.** Trisubstituted Pyrazoles of Type **10** and **11** Obtained by Regioselective Magnesiation of Pyrazoles of Type **8** and **9** with  $\text{TMP}_2\text{Mg}\cdot 2\text{LiCl}$  (**2**) and Quenching with Electrophiles

entry	substrate	electrophile	product	yield (%) <sup>a,b</sup>
1		PhCOH		71
2	<b>8c</b>	DMF		67
3		PhCOCl		75 <sup>c</sup>
4		PhCOCl		76 <sup>c</sup>
5	<b>9b</b>	Br-CH <sub>2</sub> -CH=CH <sub>2</sub>		70 <sup>d</sup>


<sup>a</sup> Isolated, analytically pure product. <sup>b</sup> Deprotonation conditions:  $\text{TMP}_2\text{Mg}\cdot 2\text{LiCl}$  (**2**; 1.1 equiv),  $-20^\circ\text{C}$ , 4 h. <sup>c</sup> Transmetalation with 1.1 equiv of  $\text{CuCN}\cdot 2\text{LiCl}$ . <sup>d</sup> Catalyzed with 5 mol % of  $\text{CuCN}\cdot 2\text{LiCl}$ .

expected ketone **10c** in 75% yield (entry 3). Similarly, *N*-methylpyrazole **9b** was magnesiated and transmetalated with  $\text{CuCN}\cdot 2\text{LiCl}$ ,<sup>19</sup> leading after reaction with benzoyl chloride and allyl bromide to the trisubstituted pyrazoles **11a** and **11b** in 70–76% yield (entries 4 and 5). Interestingly, pyrazole **8b** bearing an ester moiety at the C3 position could

**Scheme 3.** Magnesiation of Pyrazole **8b** at Position C4 using  $\text{TMPMgCl}\cdot\text{LiCl}$  (**1**)



**Scheme 4.** Synthesis of the Acaricide Tebufenpyrad (**13**) through Successive Regio- and Chemoselective Metallations



be deprotonated with the milder base  $\text{TMPMgCl}\cdot\text{LiCl}$  (**1**; 1.1 equiv,  $-30^\circ\text{C}$ , 2 h). Quenching of the resulting magnesium reagent **12** in the presence of  $\text{CuCN}\cdot 2\text{LiCl}$ <sup>19</sup> with allyl bromide afforded the allylated pyrazole **10d** in 75% yield (Scheme 3).

This functionalization of the pyrazole core was applied to the synthesis of the acaricide Tebufenpyrad (**13**).<sup>20</sup> *N*-Methylpyrazole **4b** was treated with  $\text{TMPMgCl}\cdot\text{LiCl}$  (**1**; 1.1 equiv,  $25^\circ\text{C}$ , 1 h) and quenched with  $\text{NCCO}_2\text{Et}$ , providing the expected ester **14**. Position 4 was then chlorinated via an electrophilic substitution reaction,<sup>20b,c</sup> furnishing **15** in 93% yield. The chlorine serves to activate the position C3,

so that it could be metalated using the milder base  $\text{TMP}_2\text{Zn}\cdot 2\text{MgCl}_2\cdot 2\text{LiCl}$ <sup>15</sup> (**3**). Pyrazole **15** was treated with  $\text{TMP}_2\text{Zn}\cdot 2\text{MgCl}_2\cdot 2\text{LiCl}$ <sup>15</sup> (**3**; 1.1 equiv,  $25^\circ\text{C}$ , 6 h), and subsequent addition of  $\text{I}_2$  furnished the iodopyrazole **16**. This iodide **16** undergoes a one-pot cross-coupling reaction with  $\text{Et}_3\text{In}$  generated by the reaction of  $\text{EtMgCl}$  (1.5 equiv) with  $\text{InCl}_3$  (0.5 equiv),<sup>21</sup> affording the Tebufenpyrad precursor **17** in 69% yield. Reaction with 4-*tert*-butylbenzylamine yielded Tebufenpyrad (**13**) in 75% yield (Scheme 4).

In conclusion, we have developed a new general method for regio- and chemoselective metallations of pyrazoles via successive deprotonation reactions using  $\text{TMPMgCl}\cdot\text{LiCl}$  (**1**),  $\text{TMP}_2\text{Mg}\cdot 2\text{LiCl}$  (**2**), or  $\text{TMP}_2\text{Zn}\cdot 2\text{MgCl}_2\cdot 2\text{LiCl}$  (**3**) leading to a variety of functionalized pyrazole derivatives with a regiocontrolled introduction of all substituents. Further applications to the preparation of more complex pyrazoles are currently underway in our laboratories.

**Acknowledgment.** We thank the Fonds der Chemischen Industrie, the ERC (European Research Council), and the Deutsche Forschungsgemeinschaft (DFG) for financial support. We also thank BASF AG (Ludwigshafen), Evonik Industries AG (Hanau), W. C. Heraeus GmbH, and Chemetall GmbH (Frankfurt) for the generous gift of chemicals.

**Supporting Information Available:** Experimental procedures and analytical data. This material is available free of charge via the Internet at <http://pubs.acs.org>.

OL901208D

(20) (a) Marcic, D. *Exp. Appl. Acarol.* **2005**, *36*, 177, and references therein. (b) Fustero, S.; Román, R.; Sanz-Cervera, J. F.; Simón-Fuentes, A.; Cunat, A. C.; Villanova, S.; Murguía, M. *J. Org. Chem.* **2008**, *73*, 3523. (c) Fustero, S.; Román, R.; Sanz-Cervera, J. F.; Simón-Fuentes, A.; Bueno, J. C. Villanova. *J. Org. Chem.* **2008**, *73*, 8545.

(21) (a) Pena, M. A.; Sestelo, J. P.; Sarandeses, L. A. *Synthesis* **2005**, *3*, 485. (b) Pérez, I.; Pérez-Sestelo, J.; Sarandeses, L. A. *J. Am. Chem. Soc.* **2001**, *123*, 4155.